Long-term effect of dexfenfluramine on amino acid profiles and food selection in obese patients during weight loss

International Journal of Obesity

Volumn 20, Issue 2, 1996, Pages 147-153

  Breum, L ^a,b,c   Moller S E ^c   Andersen, T ^a   Astrup, A ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Sct Hans Hospital   (Denmark)

Author keywords

Amino acids; Appetite; Appetite suppressants; Dexfenfluramine; Food selection; Obesity; Serotonin; Tryptophan; Weight loss

Indexed keywords

ANOREXIGENIC AGENT; DEXFENFLURAMINE; TRYPTOPHAN; TYROSINE;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CALORIC INTAKE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DOUBLE BLIND PROCEDURE; FAT INTAKE; FEMALE; HUMAN; MALE; OBESITY; PRIORITY JOURNAL; PROTEIN INTAKE; RANDOMIZED CONTROLLED TRIAL; WEIGHT REDUCTION;

EID: 0030034197     PISSN: 03070565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Garattini S, Buczko W, Jori A, Samanin R. The mechanism of action of d-fenfluramine. Postgrad Med J 1975; 51: 27-32.
2. Kim SH, Wurtman RJ. Selective effects of CGS 10686B, dl-fenfluramine or fluoxetine on nutrient selection. Physiol Behav 1988; 42: 319-322.
3. Leibowitz SF, Arcomano A, Hammer NJ. Potentiation of eating associated with tricyclic antidepressants during activation of alpha-adrenergic neurons in the paraventricular hypothalamus. Prog Neuro-Psychopharm 1978; 2: 349-358.
4. Leibowitz SF, Weiss GF, Shor-Possner G. Hypothalamic serotonir: pharmacological, biochemical and behaviour analyses of its feeding-suppressive actions. Clin Neuropharmacology 1988; 11(S1): S51-S71.
5. Wurtman JJ, Wurtman RJ. Fenfluramine and fluoxetine spare protein consumption while suppressing calorie intake by rats. Science 1977; 198: 1178-1180.
6. Goodall E, Silverstone T. Differential effect of d-fenfluramine and metergoline on food intake in human subjects. Appetite 1988; 11: 215-228.
7. Anderson GH. Control of protein and energy intake: role of plasma amino acids and brain neurotransmitters. Can J Physiol Pharmacol 1979; 57: 1043-1057.
8. Blundell JE. Serotonin and appetite. Neuropharmacology 1984; 23: 1537-1552.
9. Fernstrom JD. Food-induced changes in brain serotonin synthesis, is there a relationship to appetite for specific macronutrients. Appetite 1987; 8: 163-182.
10. Møller SE. Serotonin, carbohydrates and atypical depression. Pharmacol Toxicol 1992; 71: 61-71.
11. Pardridge WM, Olendorf WH. Kinetic analyses of blood-brain barrier transport of amino acids. Biochim Biophys Acta 1975; 401: 128-136.
12. Fernstrom JD, Wurtman RJ. Brain serotonin content: increase following ingestion of carbohydrate diet. Science 1971; 174: 1023-1025.
13. Leathwood P. Dietary manipulation of serotonin and behaviour. In: Huether G (ed). Amino acid availability and brain function in health and disease. Springer: Berlin, 1988, pp 275-283.
14. Lyons PM, Truswell AS. Serotonin precursor influenced by type of carbohydrate meal in healthy adults. Am J Clin Nutr 1988; 47: 433-439.
15. Møller SE. Carbohydrate/protein selection in a single meal correlated with plasma tryptophan and tyrosine ratios to neutral amino acids in fasting individuals. Physiol Behav 1986; 38: 175-183.
16. Teff KL, Young SN, Marchand L, Botez MI. Acute effect of protein and carbohydrate breakfast on human cerebrospinal fluid monoamine precursor and metabolite levels. J Neurochem 1989; 52: 235-241.
17. Young SN, Tourman SV, Teff KL, Pihl RO, Anderson GH. The effect of lowering plasma tryptophan on food selection in normal males. Pharmacol Biochem Behav 1988; 31: 149-152.
18. Guy-Grand B, Apfelbaum M, Crepaldi G, Gries A, Lefebvre P, Turner P. International trial of long-term dexfenfluramine in obesity. Lancet 1989; 2: 1142-1145.
19. Turner P. Dexfenfluramine. Its place in weight control. Drugs 1990; 39(S3): 53-62.
20. Brzezinski AA, Wurtman JJ, Wurtman RJ, Gleason R, Greenfield J, Nader T. d-Fenfluramine suppresses the increase of calorie and carbohydrate intakes and improve the mood of women with premenstrual depression. Obstet Gynecol 1990; 76: 296-301.
21. O'Rourke D, Wurtman JJ, Wurtman RJ, Chebli RN, Gleason R. Treatment of seasonal affective depresion with d-Fenfluramine. J Clin Psychiat 1989; 50: 343-347.
22. Pijl H, Koppeschaar PF, Willekens FLA, Op de Kamp I, Vldhuis HD, Meinders AE. Effect of serotonin reuptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity. Int J Obesity 1991; 15: 237-242.
23. Spring B, Wurtman JJ, Gleason R, Wurtman RJ, Kessler R. Post-smoking cessation weight gain: preventive intervention with d-fenfluramine. Pharmacol Biochem Behav 1990; 36: 431-422.
24. Wurtman JJ, Wurtman RJ, Reynolds S, Tsay R, Chew B. d-Fenfluramine suppresses snack intake among carbohydrate cravers, but not among non carbohydrate cravers. Int J Eating Disorders 1987; 6: 687-699.
25. Wurtman JJ, Wurtman RJ, Mark S, Tsay R, Gilbert W, Growdon J. d-Fenfluramine selectively suppresses carbohydrate snacking by obese subjects. Int J Eating Disorders 1985; 4: 89-99.
26. Blundell JE, Hill AJ. Do serotoninergic drugs decrease energy intake by reducing fat or carbohydrate intake? Effect of d-fenfluramine with supplemented weight increasing diets. Pharmacol Biochem Behav 1989; 31: 773-778.
27. Goodall E, Feeney S, McGuirk J, Silverstone T. A comparison of the effects of d- and l-fenfluramine and d-amphetamine on the energy and macronutrient intake in human subjects. Psychopharmacology 1992; 106: 221-227.
28. Hill AJ, Blundell JE. Sensitivity of the appetite control system in obese subjects to nutritional and serotonergic challenges. Int J Obesity 1989; 4: 219-233.
29. Caballero B, Finer N, Wurtman RJ. Plasma amino acids levels in obesity: effects of insulin resistance. In: Kaufman S, Fernstrom J, Roth R, Woo S (eds). Amino acids in health and disease: new perspectives, UCLA symposia on molecular and celluar biology. Allan R Liss: New York, 1986.
30. Russ M, Ackermann SH, Banay-Schwartz M, Shindledecker RD, Smith GP. Plasma tryptophan to large neutral amino acid ratios in depressive and normal subjects. J Affective Disorders 1990; 19: 9-14.
31. Møller SE. Plasma neutral amino acids associated with the efficacy of antidepressive treatment. A summary. In: Spiegel DA (ed). Progress in psychiatry. American Psychiatric Press: Washington DC, 1990, pp 101-129.
32. Andersen T, Astrup A, Quaade F. Dexfenfluramine as adjuvant to a low-calorie formula diet in the treatment of obesity: a randomized clinical trial. Int J Obesity 1992; 16: 35-40.
33. Møller SE. Quantitative determination of branched-chain and aromatic amino acids by ion-exchange chromatography. Analyt Biochem 1977; 79: 590-593.
34. Astrup A, Raben A. Obesity: an inherited metabolic deficiency in the control of macronutrient balance?. Eur J Clin Nutr 1992; 46: 611-620.
35. Ravussin E. Pathophysiology of obesity. Lancet 1992; 404: 404-408.
36. Lafreniere F, Lambert J, Rasio E, Serri. Effects of dexfenfluramine treatment on body weight and postprandial thermogenesis in obese subjects. A double-blind placebo controlled study. Int J Obesity 1993; 17: 25-30.
37. Livingstone MBE, Prentice AM, Strain JJ et al. Accuracy of weighted dietary records in studies of diet and health. Br Med J 1990; 300: 708-712.
38. Goodwin GM, Cowen PJ, Fairburn CG, Parry-Billings M, Calder PC, Newsholme EA. Plasma concentration of tryptophan and dieting. Br Med J 1990; 300: 1499-1500.
39. Breum L, Bjerre U, Jacobsen S, Bak J, Møller SE, Bach F, Astrup A. Long-term metabolic effects of fluoxetine in obese patients before and after weight loss [abstract]. Int J Obesity 1992; 16(S1): 17.
40. Scheen AJ, Paulusso G, Salvatore T, Lefebvre PJ. Improvement of insulin-induced glucose disposal in obese patients with NIDDM after 1-week treatment with D-fenfluramine. Diabetes Care 1991; 14: 325-332.
41. Andersen PH, Richelsen B, Bak J, Schmitz O, Møller N, Sørensen NS, Lavielle R, Pedersen O. Influence of short-term dexfenfluramine therapy on glucose and lipid metabolism in obese non-diabetic patients. Acta Endocrinologica 1993; 128: 251-258.
42. Damsbo P, Madsbad S, Henriksen JE, Beck-Nielsen H. Effect of weight loss and dexfenfluramine on glycemic control and glucose metabolism in obese NIDDM patients [abstract]. Diabetes 1991; 40(S1): 307A.
43. Pestell RG, Crock PA, Ward GM Alford FP, Best JD. Fenfluramine increases insulin action in patients with NIDDM. Diabetes Care 1989; 12: 252-258.